UnknownNCT04927260
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Leon Berard
- Principal Investigator
- MEHDI BRAHMICentre Leon Berard
- Intervention
- Patient treated by Avapritinib in real life(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (7)
- CHRU Besançon, Besançon, France
- Insitut Bergonié, Bordeaux, France
- CHU Clermont Ferrand, Clermont-Ferrand, France
- Centre Léon Bérard, Lyon, France
- Institut de Cancérologie de l'Ouest (ICO), Nantes, France
- CHU Robert Debré, Reims, France
- Institut Gustave Roussy, Villejuif, France
Collaborators
Blueprint Medicines Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04927260 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGPHASE2NCT07434843PH 2 Pemigatinib in SDH-deficient GISTDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07406633KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line SettingKumquat Biosciences Inc.
- ENROLLING BY INVITATIONPHASE2NCT07550582Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionPeking University People's Hospital
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1, PHASE2NCT07096609Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsAsan Medical Center
- RECRUITINGPHASE2NCT07559864Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentJian Li